A new pre-surgery treatment strategy for inherited breast cancer has achieved an astonishing 100% survival rate, thanks to a simple yet powerful timing tweak. A promising new treatment is offering fresh hope for patients with aggressive, inherited breast cancers. In a recent clinical trial led by Cambridge researchers, every patient who received a combination of chemotherapy and a targeted cancer drug before surgery survived the crucial three-year period following treatment. Published in Nature Communications, the study suggests this could become the most effective therapy yet for early-stage breast cancer linked to BRCA1 and BRCA2 gene mutations. These inherited forms of...